Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Results From 8 Late-Breaking Clinical Trials Presented At Heart Failure 2009
Results and updates from eight studies were presented during a late-breaking trials session at Heart Failure 2009. Reviewing them at a press conference, Professor John McMurray, President of the Heart Failure Association, described the trials" objectives and main implications.
generic viagra online
Advances Highlight Progress Being Made In The Treatment And Research Of GastroIntestinal Disorders
Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week® 2009 (DDW®), the largest and most prestigious gastroenterology meeting, from May 30 to June 4, 2009, at the McCormick Place Convention Center, Chicago, IL. DDW is the annual meeting of the American Gastroenterological Association (AGA) Institute, the largest and oldest GI society in the world. AGA Institute researchers will present exciting, cutting-edge data during the meeting that will help change the way physicians diagnose and treat GI disorders.
News of the day
BUPA Launches Breakthrough Treatment For Back And Knee Pain
New research reveals around 22 million people suffered back pain in the last year - just under half of all UK adults (45 percent)[1]. More than one in four UK adults - nearly 13 million people - suffered from knee pain in the last year. Over 80 percent of the people with back or knee pain still suffer some pain after undergoing treatment recommended by a healthcare professional. Bupa is making APOS Treatment for knee and lower back pain available in the UK for the first time. The breakthrough treatment can eliminate the need for prescription pain relief for seven out of 10 people[2].
Diagnostics

Endeavor Drug-Eluting Stent Is First To Receive CE Mark For Treating Acute Coronary Syndrome

Medtronic, Inc. (NYSE: MDT), announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE (Conformité Européene) Mark approval for treating patients with acute coronary syndrome (ACS), which includes unstable angina and acute myocardial infarction (AMI), commonly known as heart attack. Medtronic is launching the unique ACS indication for the Endeavor DES today at PCR, a large and prestigious international meeting of interventional cardiologists. At this meeting today, Prof. Martin Rothman of the London Chest Hospital in the U.K. released positive new 12Ò€òmonth data from the international realÒ€òworld registry EÒ€òFive study (n=8,314) that show comparable outcomes for Endeavor DES patients with and without ACS . "Considering the distinctive safety record of the Endeavor stent, this indication for ACS makes perfect sense," said Prof. Rothman. "Results from the EÒ€òFive study support the use of the Endeavor stent in realÒ€òworld clinical practice, including ACS patients." Clinical research shows that ACS patients are at higher risk of stent thrombosis and mortality than nonÒ€òACS patients. ACS is a complex disease state for which drugÒ€òeluting stents are sometimes avoided due to concerns over longÒ€òterm safety and patient compliance with antiplatelet medication. "Of critical importance for safety, the biocompatibility of the Endeavor stent allows rapid and complete healing of the vessel wall," explained Sean Salmon, vice president and general manager of Medtronic CardioVascular"s Coronary and Peripheral business. "We believe that this healthy healing is the key to longÒ€òterm safety and efficacy." The EÒ€òFive study demonstrated no statistically significant difference on the primary endpoint - the rate of major adverse cardiac events (MACE) at one year - between ACS patients (7.8 percent, n=3,973) and nonÒ€òACS patients (7.2 percent, n=4,341). Rates of death, MI and late stent thrombosis (LST) at one year were similarly low and comparable between the two groups. - AllÒ€òcause mortality - 2.7% ACS, 2.2%, nonÒ€òACS - Cardiac death - 2.0% ACS, 1.5% nonÒ€òACS - MI - 1.8% ACS, 1.5% nonÒ€òACS - Cardiac death + MI - 3.4% ACS, 2.7% nonÒ€òACS - LST (ARC def/prob) - 0.5% ACS, 0.3% nonÒ€òACS Low and similar rates of standard efficacy measures were also observed, including target lesion revascularization (TLR), target vessel revascularization (TVR) and target vessel failure (TVF). On all these measures, there were no statistically significant differences between the ACS and nonÒ€òACS groups. Medtronic"s Endeavor stent originally received the CE mark in August 2005 as a treatment for coronary artery disease. This latest approval enables Medtronic to market the Endeavor DES specifically for ACS patients in the European Union, and all other countries that recognize the CE Mark. These countries do not include the United States or Japan, where the Endeavor DES is also commercially available but is not indicated for ACS patients. Medtronic, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009